.png){kind=icon}
.png){kind=icon}
Return
Editorial: EGFR-targeted therapy in lung cancer: unraveling molecular regulation; overcoming resistance; and advancing precision clinical practice
.png){kind=icon}
OA
AI
H
Y
S
S
K
DOI：10.3389/fmolb.2026.1936450.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Lung cancer remains the leading cause of cancer-related mortality worldwide; with nonsmall cell lung cancer (NSCLC) accounting for approximately 85% of all cases. Epidermal growth factor receptor (EGFR) mutations are among the most common oncogenic driver alterations in NSCLC and have led to the development of EGFR-targeted tyrosine kinase inhibitors (TKIs); which have become the standard first-line treatment for patients with EGFR-
Keywords:
EGFR
resistance
targeted therapy
lung cancer
precision medicine
Journal
IF:
4
Papers:
6.0K
Citations:
2.0W
Organization
Cited Papers